SANOFI US SERVICES INC. for SANOFI US SERVICES INC
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 18, 2008 | $1,210,000 | Replaced |
| 1st Quarter - Amendment (this page) | Dec 18, 2008 | $1,190,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Environment/Superfund ENV
pharmaceuticals in the environment
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
Copyright/Patent/Trademark CPT
S. 1145 "The Patent Reform Act of 2007". All provisions
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDDIE D EVANS | — |
| EDWARD GREISSING | — |
Taxation/Internal Revenue Code TAX
Provisions related to the extension of the US R&D tax credit in HR1712 "Research and Development Tax Credit Act of 2007" and HR2138 "Investment in America Act of 2007"
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANN TAYLOR | — |
Health Issues HCR
Deep Vein Thrombosis awareness; issues related to follow-on biologics including all related provisions in HR 1956 "Patient Protection and Innovative Biologic Medicines Act of 2007", and S 1695 "Biologics Price Competition and Innovation Act of 2007"; comparative effectiveness; the Together Rx Access program; HR 1585 and S 567, "National Defense Authorization Act for FY2008"; HR 3222 and HR 2764, "Department of Defense Appropriations Act, 2008", and HR 4986, "National Defense Authorization Act for Fiscal Year 2008": provisions related to procurement and reimbursement for services by the TRICARE system and the quality of healthcare delivered by the Defense Health System
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CLARK | — |
| EDWARD GREISSING | — |
| RICHARD M HODGE | — |
| SAIRA SULTAN | — |
Medicare/Medicaid MMM
compendia coverage of Medicare Part B drugs, including such related provisions in HR 3162 "Children's Health and Medicare Protection Act of 2007"; Deep Vein Thrombosis issues related to Medicare Part A Regulation and the Medicare Part D Call Letter.
Foreign entity interest: To the degree that such public policies, either laws or regulations, impact sanofi-aventis U.S. Inc., so too sanofi-aventis SA, the foreign parent company identified on Form LD-1, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK COIN | — |
| SAIRA SULTAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.